Sign in to NCBI

Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Neurology. 2005 Dec 13;65(11):1834-6.

    Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

    Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M.

    Source

    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kimberly.ferrante@umassmed.edu

    Abstract

    An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

    PMID:
    16344537
    [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances, Grant Support

    Publication Types

    MeSH Terms

    Substances

    Grant Support

    LinkOut - more resources

    Full Text Sources

    Other Literature Sources

    Medical

      Supplemental Content

      Icon for HighWire
      Loading ...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk